Dissemination of antibiotic resistance in Enterobacteriaceae mediated by AmpC b-lactamase, extended-spectrum b-lactamase (ESBL) and metallo-b-lactamase (MBL) is clinically significant. A simple and relatively quick method for the detection of these resistance phenotypes would greatly improve chemotherapeutic recommendation. This technology would provide valuable input in our surveillance of resistance on a global stage, particularly if the methodology could be applicable to resource-poor settings. A resazurin microtitre plate (RMP) assay incorporating cloxacillin, clavulanic acid and EDTA for the rapid phenotypic identification of AmpC, ESBL and MBL and the co-existence of b-lactamases has been developed. A total of 47 molecularly characterized Enterobacteriaceae clinical isolates producing AmpCs, ESBLs, co-producers of ESBL and AmpC, MBLs and co-producers of ESBL and MBL were phenotypically examined using the RMP assay. The ceftazidime-and cefotaxime-based RMP assays successfully detected all 16 AmpC, 14 ESBL and 9 MBL producers, 6 ESBL-AmpC co-producers and 2 ESBL-MBL co-producers without false-positive results. The ceftazidime-based assay was more reliable in detecting AmpC alone, while the cefotaxime-based assay performed better in identifying co-producers of ESBL and AmpC. There was no difference in the detection of ESBL and MBL producers. The findings of the present study suggest that use of the RMP assay with particular b-lactamase inhibitors explicitly detects three different b-lactamases, as well as co-existence of b-lactamases, within 6 h of initial isolation of the pathogen. This assay is applicable to carry out in any laboratory, is cost-effective and is easy to interpret. It could be implemented in screening patients and controlling infection and for surveillance purposes.
INTRODUCTION
Infections caused by multidrug-resistant Enterobacteriaceae are among the most serious threats to human health both in hospital and the community (Tangden & Giske, 2015) . b-Lactam antibiotics are commonly used to treat bacterial infections due to their low toxicity and high efficacy. b-Lactams bind to the penicillin-binding proteins of the bacterial cell wall, causing peptidoglycan disruption and cell lysis (Drawz & Bonomo, 2010) . The continuous exposure of bacteria to a variety of b-lactams has triggered the production of b-lactamase enzymes [AmpC, extended-spectrum blactamase (ESBL) and metallo-b-lactamase (MBL)], the most common mechanism of b-lactam resistance among Enterobacteriaceae. The production of b-lactamases mediated by both chromosomal and plasmid genes (subject to inducible expression) is a crucial mechanism of antibiotic resistance. AmpC b-lactamases were the first bacterial enzymes found to inactivate penicillin, which was first identified in Escherichia coli in 1940 prior to penicillins being medically introduced (Jacoby, 2009 ). Plasmid-mediated AmpC b-lactamase (pAmpC)-producing Enterobacteriaceae can confer resistance to multiple antibiotics, such as penicillins, oxyiminocephalosporins [e.g. cefotaxime (CTX), ceftazidime (CAZ) and ceftriaxone] and 7-a-methoxycephalosporins (e.g. cefoxitin and cefotetan) (Gupta et al., 2012; Bush et al., 1995) . CMY-type b-lactamases, especially CMY-2, are highly prevalent pAmpCs in Escherichia coli that have been commonly identified in many regions of the world (Doi et al., 2010; Liebana et al., 2013) . These enzymes are known to be inhibited by boronic acid (BA) and its derivatives (Beesley et al., 1983) , along with cloxacillin (CX) (Jacoby, 2009) . BA and it derivatives are known to form reversible covalent bonds with serine protease inhibiting their activities; Kiener & Waley (1978) first demonstrated that BA derivatives inhibit a blactamase produced by Bacillus cereus.
Enterobacteriaceae can also produce powerful enzymes called ESBLs, which characteristically confer resistance to penicillins, cephalosporins and monobactams but remain susceptible to cephamycins, carbapenems and the b-lactamase inhibitors [clavulanic acid (CA), tazobactam and sulbactam] (Bradford, 2001) . MS testing of inactivation mechanisms and Raman microscopy have demonstrated that the blactamase inhibitors, CA, tazobactam and sulbactam, undergo complex reactions starting with an acyl-enzyme synthesis (Imtiaz et al., 1993; Kalp et al., 2009) .
The majority of ESBL-producing clinical isolates of Enterobacteriaceae harbour TEM-, SHV-and CTX-M-type blactamases. These enzymes have gained medical significance in both hospital and community settings across all ages and demographics (Lukac et al., 2015) . Furthermore, carbapenem-inactivating b-lactamase, namely MBL, has been identified with increasing prevalence over the past few years (Patrice et al., 2011) . MBL can hydrolyse all classes of bicyclic b-lactams (penicillins, cephalosporins and carbapenems) and all commercially available b-lactamase inhibitors (such as CA) but lacks hydrolytic activity toward monocyclic b-lactams (monobactams) (Bebrone, 2007) . For more information regarding b-lactam structures, the reader is referred to Bush & Fisher (2011) . The activity of this enzyme is facilitated by zinc ions to degrade b-lactams and is inhibited by metal-chelating EDTA and dipicolinic acid (Walsh et al., 2005) . Imipenemase (IMP), Verona integron-encoded metallo-b-lactamase (VIM) and New Delhi metallo-b-lactamase (NDM) are common widespread MBLs. These metalloenzymes were frequently identified in Pseudomonas aeruginosa and Acinetobacter spp., but currently an increasing prevalence of these has been documented in Enterobacteriaceae worldwide (Patel & Bonomo, 2013) .
The early detection of the presence of these resistant strains at the phenotypic level would aid infection-control practitioners to minimize the dissemination of these bacteria and also help to select appropriate antimicrobial treatment, decreasing morbidity and mortality (Pitout & Laupland, 2008) . The development of a rapid phenotypic method for the identification of these b-lactamase-producing strains in clinical practice is a challenging issue. The resazurin (Alamar blue) reduction assay is a simple and inexpensive colorimetric method that has extensively been used as an indicator for cell growth, cell viability, toxicity and indirect antimicrobial susceptibility testing. This dye is non-toxic to cells and stable in culture media. A blue-coloured resazurin is irreversibly converted to a pink-coloured resorufin by active cells (O'Brien et al., 2000; Palomino et al., 2002) . The present study uses the resazurin dye in conjunction with three distinct b-lactamase inhibitors, CX (AmpC inhibitor), CA (ESBL inhibitor) and EDTA (MBL inhibitor), for the phenotypic detection of AmpC, ESBL, MBL and co-expression of b-lactamases. The use of multiple blactamase inhibitors can allow identification and differentiation between isolates, producing a single enzyme type and co-producing multiple enzymes. In detail, a co-producing pAmpC and ESBL will grow when exposed to CA alone as the AmpC b-lactamase can hydrolyse cephalosporins, resulting in high MIC values. However, it will not grow in the presence of CA and CX inhibitors.
METHODS
Bacterial isolates, chemicals and antibiotics. A total of 47 blactamase-producing Enterobacteriaceae isolates (collected from local hospitals between 2012 and 2015) were used in this study. The bacterial strains included Escherichia coli (n=15), Klebsiella pneumoniae (n=16), Enterobacter aerogenes (n=2), Enterobacter cloacae (n=9), Morganella morganii (n=1), Citrobacter freundii (n=3) and Klebsiella ozaenae (n=1); 16 were AmpC producers, 14 were ESBL producers, 6 were ESBL and AmpC co-producers, 9 were MBL producers and 2 were ESBL and MBL co-producers (Table 1 ). The control strains were Escherichia coli ATCC 25922 (non-b-lactamase producer), Enterobacter cloacae ATCC BAA-1143 (bla ), Escherichia coli NCTC 13352 (bla ) and Escherichia coli NCTC 13353 (bla ). All organisms had been identified by biochemical, phenotypic and molecular tests including combined disc, multiplex PCR and sequencing methods as previously described (P erez-P erez & Hanson, 2002; Woodford, 2010; Roschanski et al., 2014) . All antibiotics and chemicals used were purchased from Sigma-Aldrich. Mueller-Hinton broth powder was obtained from Scientific Laboratory AmpC, ESBL and MBL detection using resazurin Table 1 .
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MICs of CTX-based (µg ml Supplies. Antibiotics and b-lactamase inhibitors were prepared in accordance with the recommendation of the manufacturers.
Resazurin microtitre plate assay. The production of ESBL, AmpC, MBL and co-b-lactamases was phenotypically detected using the resazurin microtitre plate (RMP) assay based upon the broth microdilution method. An 18 h culture of the appropriate test bacterium was pelleted for 10 min and washed twice with normal saline at 5000 g for 5 min before adjustment to a 0. (recommended by the CLSI). The concentrations of the CX and EDTA inhibitors have been optimized, but data are not shown. The assay was repeated in triplicate, including the following: sterile water (negative control) and inoculum with resazurin without the presence of any antibiotics or inhibitors (positive control). Following incubation at 37 C, the lowest concentration showing no colorimetric change from blue to pink within 6 h was considered as the MIC value. An eightfold or greater decrease in MIC value for wells where, e.g. ESBL inhibitor is present, compared with the MIC value for wells without ESBL inhibitor, is considered a positive result for ESBL production (exhibiting a resistant phenotype). In the case above, an MIC ratio lower than 8 indicates a sensitive strain (negative result, Table 2 ) (Yagi et al., 2005; Jeong et al., 2009; Clinical Laboratory Standards Institute, 2012) .
RESULTS AND DISCUSSION
b-Lactam antibiotics are most frequently prescribed for the treatment of infections caused by Gram-negative bacteria, in particular Enterobacteriaceae. Resistance to b-lactams is mediated by both plasmid-encoded and chromosomally encoded b-lactamases. The rapid global spread of these resistant bacteria is facilitated by inter-and intra-species gene transmission, poor sanitation and hygiene, increasing global trade, international travel and tourism and antibiotic misuse (Rogers et al., 2011; Aung et al., 2012; Laxminarayan et al., 2013) . The consequence is increased treatment failure, morbidity and mortality. The development of quick and accurate methods for the detection and characterization of different types of b-lactamase remains an urgent necessity. Early detection is crucial in guiding appropriate antimicrobial therapy. Current methods of detection include disc diffusion assays, broth microdilution methods and multiplex PCR (Jacoby, 2009; Jeong et al., 2009; Gupta et al., 2012) . Moreover, some phenotypic assays require a freeze-thawed (five to seven times) concentrated pellet rather than whole cells (Nasim et al., 2004; Lee et al., 2005) . All the above detection methods for the production of b-lactamase are either time consuming (approximately 24-48 h after initial isolation of the pathogen) or expensive (Nordmann et al., 2012) . Here, we developed an RMP assay with inhibitor-based methods for the early laboratory phenotypic detection of ESBL, AmpC, MBL and co-production of b-lactamases. The results are described in Table 1 . This diagnostic test can play an important role in guiding clinicians to appropriate antibiotic administration and minimizing treatment failure. b-Lactamase-producing isolates are often resistant to multiple antibiotics, making problematic the decision regarding the appropriate antibiotic (Tangden & Giske, 2015) .
Interpretation of the findings from the RMP assay was very simple and clear, as illustrated in Fig. 1 . The results showed that the RMP CAZ-based assay was more reliable than the CTX-based assay for early laboratory AmpC detection. This is particularly important for Enterobacter aerogenes and Enterobacter cloacae infections, where a strain is originally susceptible to an antibiotic (cephalosporins) but later becomes resistant (Jacoby, 2009 ). An eightfold or higher MIC ratio was observed only for AmpC producers when comparing the well without CX to other wells. According to the CLSI, this value (an eightfold or higher increase in MIC) indicates a resistant phenotype (positive result, Table 2 ). For these AmpC producers, other MIC ratios revealed values lower than 8, which indicated negative results for ESBL and MBL producers. The CAZ-based assay successfully detected 15 of all 15 AmpC-producing isolates, while 14 of 15 strains were detected by the CTX-based RMP assay. The AmpC control strain (Enterobacter cloacae BAA-1143) clearly showed hyperproduction of AmpC b-lactamase, as indicated by a high MIC value in the well without an AmpC inhibitor (Table 1 ). The production of AmpC b-lactamase in Gram-negative pathogens, especially Enterobacteriaceae, is clinically important (Jacoby, 2009 ). Accurate and rapid detection methods for these enzymes should be urgently developed. This would ensure effective antimicrobial therapy and improve clinical management as a consequence of clinical failure in the treatment of AmpC producers with broad-spectrum cephalosporins (Polsfuss et al., 2011) . CX is well described as an AmpC b-lactamase inhibitor but, as with all phenotypic tests, it cannot distinguish between plasmid-mediated and chromosome-borne AmpCs (Jacoby, AmpC, ESBL and MBL detection using resazurin
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). This study found that CAZ in conjunction with CX and EDTA was more efficient in early laboratory detection of AmpC-producing Enterobacteriaceae compared with the CTX-based assay. We suggest that this may be due to the AmpC enzyme having a greater affinity for CAZ over CTX. This result is consistent with a previous report where CAZ showed the best performance compared with CTX, cefmetazole or moxalactam in combination with 3-aminophenylboronic acid in the detection of AmpC b-lactamases (Yagi et al., 2005) . Another previous research study reported no difference in sensitivity and specificity between CTX-and CAZ-based detection in the presence of CA with and without BA in detection of pAmpC (Jeong et al., 2009) . In the present study, some AmpC producers such as K. ; EDTA, 0.5 mM.
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The MIC ratio for wells without CA compared to wells with CA gave a value !8 in all tested ESBL-producing Enterobacteriaceae used in this study. The findings unambiguously indicated that both CAZ-and CTX-based assays gave reproducible results in detecting all ESBL isolates examined. Even though the CLSI has recommended a confirmatory test for ESBL-producing Enterobacteriaceae, previous reports found that using CTX and CAZ alone and in combination with CA demonstrated a high percentage (25 %) of false-negative results (16 out of 64) in detection of ESBL producers due to co-production of b-lactamase enzymes (Jeong et al., 2009 ). In the current study, inhibitor-based methods using three different blactamase inhibitors were applied to improve the sensitivity and specificity for phenotypic detection of ESBL in clinical isolates of Enterobacteriaceae. This modification allowed the successful identification of all ESBLs evaluated as part of this study in both CAZ-and CTX-based assays. Several techniques for detecting the production of ESBL have been proposed, such as double-disc synergy test, Etest and automated methods. The sensitivities and specificities for the double-disc test and Etest were 80 % to 95 %, while automated susceptibility methods were 80 % to 99 % (Drieux et al., 2008; Gazin et al., 2012) . In addition, the ESBL Nordmann/Dortet/Poirel test has been developed for rapid detection with an excellent sensitivity and specificity of 92.6 % and 100 %, respectively. However, this test was limited to detection of ESBL without the presence of AmpC or other b-lactamases (Nordmann et al., 2012) .
All MBL producers were detected by the RMP assay, including nine MBL-producing isolates and two co-producers of ESBL and MBL. The CTX-based assay gave similar results to the CAZ-based assay for the rapid phenotypic detection of MBL producers. The MIC ratio of non-b-lactamaseproducing Escherichia coli ATCC 25922 (comparing all wells with different combinations of b-lactamase inhibitors) for both CTX-and CAZ-based assays was 1, suggesting no ESBL, AmpC and MBL production in this bacterium. A raised global dissemination of MBL-producing Enterobacteriaceae has drawn researchers to develop reliable techniques for the detection of MBLs (Hattori et al., 2013) . Yan et al. (2004) conducted double-disc, combined disc and Etest techniques for the detection of Gram-negative bacilli producing MBLs. They found that the 2-mercaptopropionic acid double-disc test using CAZ and cefepime, with and without CA, exhibited the highest sensitivity (100 %) compared with the combined disc test (86.7 %) and Etest (36.7 %). Even the double-disc test showed high sensitivity, but there were some disadvantages, including subjective interpretation of results in some samples and also volatile and odorous properties of 2-mercaptopropionic acid (Yan et al., 2004) . More recently, double-disc synergy tests using sodium mercaptoacetic acid (SMA) and EDTA as MBL inhibitors and CAZ, imipenem and meropenem as indicator antibiotics have emerged. The results showed that CAZ in combination with SMA can detect only MBL-producing strains, whereas a combination of meropenem and SMA revealed the best performance (sensitivity, 79.1 %; specificity, 100 %) in detection of co-production of b-lactamases (Hattori et al., 2013) . Yagi et al. (2005) also suggested the broth microdilution method incorporating CAZ or CTX with SMA for successful detection of IMP-type MBL. Our findings revealed a good performance in the RMP assay for either MBL alone or in combination with ESBL.
ESBL and AmpC co-producers were positively detected as indicated by a !8 MIC ratio for wells containing either CA or CX compared to wells containing both CA and CX. The CTX-based RMP assay was more reliable in phenotypic characterization of the co-existence of ESBL and AmpC blactamase compared with the CAZ-based RMP assay ( Table 1 ). The CTX-based RMP assay correctly detected coproduction of ESBL and AmpC b-lactamase in all six isolates, confirmed by molecular methods. The CAZ-based RMP assay failed to detect co-production of both ESBL and AmpC in three of six isolates (three false-negative results).
In two of these three isolates demonstrating false-negative results, the CAZ-based RMP assay detected AmpC but failed to detect ESBL production. Molecular characterization confirmed the presence of CTX-M-type ESBL genes for these two isolates. CTX-M b-lactamases typically have potent hydrolytic activity against CTX, hence the name, while some strains have only marginal effects on MICs of CAZ (Poirel et al., 2002) . A higher level of resistance to CTX compared with CAZ could explain why the CTXbased RMP assay was more reliable in detecting CTX-Mtype ESBL in these co-producers.
Co-production of different types of b-lactamase in the same strain is one of the most common causes of phenotypic detection failure. The most prevalent isolates co-producing pAmpCs and ESBLs are K. pneumoniae and Escherichia coli (Goossens & Grabein, 2005) . The production of co-blactamases may result in false-negative tests for the detection of ESBLs or AmpCs, due to the ability of the isolate to grow in the presence of CA (ESBL inhibitor) or CX (AmpC inhibitor) individually but not when both are present at the same time (Coudron, 2005) . A method that can distinguish between ESBLs and pAmpCs is important for both treatment and epidemiology (Song et al., 2007) . Furthermore, coexpression of MBL together with ESBLs (commonly CTX-M type) and AmpC b-lactamases (mostly CMY enzymes) appears to be difficult to detect. Consequently, these may be a major cause of false-negative tests for detection of co-MBL, AmpC and ESBL in Gram-negative pathogens (Hattori et al., 2013; Tangden & Giske, 2015 (Yagi et al., 2005) . The present study using the RMP assay allows for the detection of ESBLs, AmpCs, MBLs and co-producers within 6 h following initial isolation of pathogen. RMP assays could allow clinicians to detect these enzymes in rural clinical laboratories in resource-poor settings.
Phenotypic tests for b-lactamase production are carried out in most clinical diagnostic laboratories because they are easy to implement and are cost-effective. This detection is important in terms of epidemiological purposes and restriction of the dissemination of b-lactamase-mediated resistance mechanisms (Poulou et al., 2014) . Phenotypic tests alone cannot distinguish between the specific bla genes of b-lactamases (TEM, SHV and CTX for ESBLs, CMY and MOX for AmpCs and IMP, NDM and VIM for MBLs) (Pitout & Laupland, 2008; Pitout et al., 2010) ; therefore, several reference laboratories use molecular methods for identification of those b-lactamase-encoded genes. Molecular approaches are restricted largely to reference laboratories for epidemiological studies because of the complexity and diversity of distinct point mutations of b-lactamases (Sundsfjord et al., 2004 ).
Although we used small samples of clinical isolates, a previous study found that use of CTX or CAZ combined with CA for detecting ESBL and CTX or CAZ plus BA for identifying pAmpC demonstrated 100 % in both sensitivity and specificity (Jeong et al., 2009 ). In our study, the RMP assay detected all ESBL, AmpC and ESBL-AmpC co-producers. This assay can successfully distinguish co-expression of ESBL and AmpC or ESBL and MBL in the same strain. In future work, isolates with other resistance mechanisms, including alteration of permeability of bacterial membrane and modification of membrane proteins, should be included in total isolates screened with RMP assay. The assay could also be developed to detect other carbapenemase types, e.g. K. pneumoniae carbapenemase (KPC) enzymes. BA compounds are appropriate inhibitors of KPC enzymes and have been successfully used in combination disc tests for phenotypic detection of KPC enzymes, although they also rapidly inhibit class C AmpC enzymes. The use of a carbapenem antibiotic substrate in combination with BA would allow differentiation between AmpC producers and KPC-producing isolates (Song et al., 2007; Tan et al., 2008) . The early detection of b-lactamase enzymes may reduce a delay in the initiation of appropriate antimicrobial therapy and could produce effective treatment. RMP assay is a useful method that can detect and characterize ESBL, AmpC, MBL and co-production of ESBL and AmpC or ESBL and MBL within 6 h following initial isolation of pathogen. It could be implemented in microbiological diagnostic laboratories in resource-poor areas to help clinicians screen patients, control infection and provide epidemiological surveillance.
